Rapport Therapeutics Q2 2026: $56.6M Net Loss, $436.1M Cash Runway into H2 2029, and RAP-219 Phase 3 Launch

summarizeSummary

Rapport Therapeutics posted a $56.6M net loss for Q2 2026 and held $436.1M in cash, funding operations into H2 2029. Phase 3 trials for RAP-219 in focal onset seizures have begun, and Phase 2 bipolar mania data are expected in October 2026.

check_boxKey Events · Earnings and Guidance · RAPP

• Q2 2026 Net Loss Widens

  The net loss reached $56.6 million, up from $26.7 million in Q2 2025, as R&D expenses climbed $28.7 million to $51.4 million to support advancing clinical programs.

• Cash Runway Extended to H2 2029

  With $436.1 million in cash, cash equivalents, and short-term investments at the end of Q2 2026, operations are funded into the second half of 2029.

• RAP-219 Phase 3 Program Initiated

  Patient enrollment has begun in the FOCUS 1 and FOCUS 2 pivotal trials for focal onset seizures, following China NMPA IND approval, with recruitment expected to start in Q4 2026.

• Bipolar Mania Phase 2 Data in October 2026

  Topline results from the Phase 2 trial of RAP-219 in bipolar mania are anticipated in October 2026; the trial has been modified to potentially serve as confirmatory evidence of effectiveness.

auto_awesomeAnalysis · RAPP · Life Sciences

Rapport Therapeutics' Q2 2026 update pairs financials with a pipeline leap that meaningfully advances the RAP-219 program. Enrollment is underway in the Phase 3 FOCUS 1 and FOCUS 2 trials for focal onset seizures, while the Phase 2 bipolar mania study remains on track for topline data in October 2026 — a near-term catalyst. A cash position of $436.1 million extends the runway into the second half of 2029, easing near-term financing concerns. The net loss widened to $56.6 million from $26.7 million a year ago, reflecting higher R&D spending as the pipeline progresses. For a clinical-stage biotech, the combination of pivotal trial initiation, a clear catalyst timeline, and a fortified balance sheet makes this a notable update.